GlassScriptPhysician profile
Arthi Rajagopal
NPI 1720279813
$4,894.93
in general payments reported to CMS, 2019-2025
33 companies · $872 in 2025
The $872 reported for 2025 was more than what 75% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $491 · 2020: $294 · 2021: $661 · 2022: $676 · 2023: $887 · 2024: $1,013 · 2025: $872.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,771 · Education: $1.01.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,771.20 |
| Education | $1.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,440.30 | 2019-2025 | Farxiga, Lokelma |
| Veloxis Pharmaceuticals, INC. | $657.41 | 2019-2025 | Envarsus |
| Vifor Pharma, INC. | $365.54 | 2019-2025 | Veltassa |
| Alexion Pharmaceuticals, INC. | $260.70 | 2019-2025 | Ultomiris |
| Amgen INC. | $227.05 | 2024-2025 | Krystexxa |
| Cormedix INC. | $207.93 | 2024-2025 | Defencath, Defencath |
| Merck Sharp & Dohme LLC | $194.63 | 2024-2025 | Prevymis |
| Glaxosmithkline, LLC. | $154.77 | 2023-2024 | Benlysta |
| Fresenius USA Marketing, INC. | $139.73 | 2024 | |
| Nxstage Medical, INC. | $138.14 | 2021-2025 | Nxstage Cartridge Express, Nxstage System One |
| Aurinia Pharma U.S., INC. | $131.71 | 2023-2025 | Lupkynis |
| Opko Pharmaceuticals, LLC | $128.70 | 2019-2024 | Rayaldee |
| Travere Therapeutics, INC. | $104.60 | 2022-2025 | |
| La Jolla Pharmaceutical Company | $98.86 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $96.95 | 2019-2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $91.86 | 2019-2025 | Jynarque |
| Bayer Healthcare Pharmaceuticals INC. | $72.56 | 2021-2025 | |
| Mallinckrodt Hospital Products INC. | $69.16 | 2021-2025 | Acthar |
| Amarin Pharma, INC. | $49.25 | 2019-2021 | |
| Mallinckrodt Enterprises LLC | $28.85 | 2019 | |
| Eisai INC. | $28.57 | 2020 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $28.56 | 2025 | |
| Novo Nordisk INC | $25.92 | 2025 | Rivfloza |
| Horizon Therapeutics Plc | $25.65 | 2023 | Krystexxa |
| Akebia Therapeutics INC | $19.89 | 2025 | Vafseo |
| Apellis Pharmaceuticals, INC. | $19.30 | 2025 | Empaveli |
| Ani Pharmaceuticals, INC. | $16.99 | 2024 | Purified Cortrophin Gel |
| Sanofi-Aventis U.S. LLC | $16.20 | 2021 | |
| Chiesi USA, INC. | $14.38 | 2019 | |
| Ironwood Pharmaceuticals, INC | $14.24 | 2020 | |
| Becton, Dickinson and Company | $14.16 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $12.37 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arthi Rajagopal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.